Monlunabant shows significant and clinically meaningful weight loss over 16 weeks in patients with obesity and metabolic ...

An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On October 30, 2025, Corbus Pharmaceuticals announced an underwritten ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today ...

a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. Forward-Looking Statements Statements in this press release that ...

Corbus Pharmaceuticals ( ($CRBP) ) has shared an announcement. On October 18, 2025, Corbus Pharmaceuticals announced data from its Phase 1/2 ...

Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.

Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms, leaving millions with conditions that traditional pharma cannot cure. New FDA guidances ...

Kidney and cardiovascular outcomes were similar between liraglutide, dulaglutide, and semaglutide among patients with type 2 diabetes.